When should we start screening for hydroxychloroquine retinopathy?
| Errataetall: |
CommentOn: Rheumatology (Oxford). 2022 Aug 3;61(8):3172-3179. - PMID 34788400 |
|---|---|
| Medienart: |
E-Artikel |
| Erscheinungsjahr: |
2022 |
|---|---|
| Erschienen: |
2022 |
| Enthalten in: |
Zur Gesamtaufnahme - volume:61 |
|---|---|
| Enthalten in: |
Rheumatology (Oxford, England) - 61(2022), 8 vom: 03. Aug., Seite 3097-3098 |
| Sprache: |
Englisch |
|---|
| Beteiligte Personen: |
Alveyn, Edward [VerfasserIn] |
|---|
| Links: |
|---|
| Themen: |
4QWG6N8QKH |
|---|
| Anmerkungen: |
Date Completed 05.08.2022 Date Revised 17.08.2022 published: Print CommentOn: Rheumatology (Oxford). 2022 Aug 3;61(8):3172-3179. - PMID 34788400 Citation Status MEDLINE |
|---|
| doi: |
10.1093/rheumatology/keac043 |
|---|
| funding: |
|
|---|---|
| Förderinstitution / Projekttitel: |
|
| PPN (Katalog-ID): |
NLM336714696 |
|---|
| LEADER | 01000naa a22002652 4500 | ||
|---|---|---|---|
| 001 | NLM336714696 | ||
| 003 | DE-627 | ||
| 005 | 20231225232753.0 | ||
| 007 | cr uuu---uuuuu | ||
| 008 | 231225s2022 xx |||||o 00| ||eng c | ||
| 024 | 7 | |a 10.1093/rheumatology/keac043 |2 doi | |
| 028 | 5 | 2 | |a pubmed24n1122.xml |
| 035 | |a (DE-627)NLM336714696 | ||
| 035 | |a (NLM)35139184 | ||
| 040 | |a DE-627 |b ger |c DE-627 |e rakwb | ||
| 041 | |a eng | ||
| 100 | 1 | |a Alveyn, Edward |e verfasserin |4 aut | |
| 245 | 1 | 0 | |a When should we start screening for hydroxychloroquine retinopathy? |
| 264 | 1 | |c 2022 | |
| 336 | |a Text |b txt |2 rdacontent | ||
| 337 | |a ƒaComputermedien |b c |2 rdamedia | ||
| 338 | |a ƒa Online-Ressource |b cr |2 rdacarrier | ||
| 500 | |a Date Completed 05.08.2022 | ||
| 500 | |a Date Revised 17.08.2022 | ||
| 500 | |a published: Print | ||
| 500 | |a CommentOn: Rheumatology (Oxford). 2022 Aug 3;61(8):3172-3179. - PMID 34788400 | ||
| 500 | |a Citation Status MEDLINE | ||
| 650 | 4 | |a Editorial | |
| 650 | 4 | |a Comment | |
| 650 | 7 | |a Antirheumatic Agents |2 NLM | |
| 650 | 7 | |a Hydroxychloroquine |2 NLM | |
| 650 | 7 | |a 4QWG6N8QKH |2 NLM | |
| 700 | 1 | |a Galloway, James |e verfasserin |4 aut | |
| 773 | 0 | 8 | |i Enthalten in |t Rheumatology (Oxford, England) |d 1999 |g 61(2022), 8 vom: 03. Aug., Seite 3097-3098 |w (DE-627)NLM102581908 |x 1462-0332 |7 nnns |
| 773 | 1 | 8 | |g volume:61 |g year:2022 |g number:8 |g day:03 |g month:08 |g pages:3097-3098 |
| 856 | 4 | 0 | |u http://dx.doi.org/10.1093/rheumatology/keac043 |3 Volltext |
| 912 | |a GBV_USEFLAG_A | ||
| 912 | |a GBV_NLM | ||
| 951 | |a AR | ||
| 952 | |d 61 |j 2022 |e 8 |b 03 |c 08 |h 3097-3098 | ||